Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
Julia D. Wallukule, Daniela Berg, Claudia Wolff, Rupert Langer, Kai Tran, Julie Illi, Virginia Espina, Marialehna Pierobon, Jianghong Deng, Angela DeMichele, Axel Walch, Holger Bronger, Ingrid Becker, Christine Walldor, Heinz Höffer, Laura Eezerman on behalf of the I-SPY 1 TRIAL Investigators, Lance A. Liotta, Karl-Friedrich Becker, and Emanuel F. Petricoin III

Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Koji Tamada, Degui Geng, Yukimi Sakoda, Navneeta Bansal, Ratika Srivastava, Zhaoyang Li, and Eduard Davila

IMAGING, DIAGNOSIS, PROGNOSIS

MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation
Martin Wermke, Anne Schmidt, Jan Moritz Middeke, Katja Seckel, Malte von Bonin, Claudia Schonefeldt, Sabine Mair, Verena Ploedeck, Michael Laniado, Gunter Weiss, Johannes Schetelig, Gerhard Ehninger, Igor Theurl, Martin Bornhauser, and Uwe Platzbecker

Combretastatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging
Thomas Nielsen, Lise Bentzen, Michael Pedersen, Trine Tramm, Paul F.J.W. Rijken, Johan Buusink, Michael R. Horsman, and Leif Østergaard
CANCER THERAPY: CLINICAL

Publication and Reporting Conduct for Pharmacodynamic Analyses of Tumor Tissue in Early-Phase Oncology Trials
Georgina A. Freeman and Jonathan Kimmelman
See commentary p. 6398

Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
Paola Filipazzi, Lorenzo Pilla, Luigi Mariani, Roberto Patuzzo, Chiara Castelli, Chiara Carmisacchi, Andrea Maurich, Agata Cova, Gianluigi Rigamonti, Felicetta Giardino, Annabella Di Florio, Marco Asiol, Paola Frati, Gloria Sovena, Paola Squarcina, Michele Maio, Riccardo Danielli, Vanna Chiarion-Sileni, Antonello Villa, Claudia Lombardo, Gabrina Tragni, Mario Santinami, Giorgio Parmiani, and Licia Rivoltini

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

ABOUT THE COVER

Expression of GFP-tagged PROX1 in colon cancer cells reduced E-cadherin and induced epithelial–mesenchymal transition. We found that PROX1 activated miR-9 expression to attenuate E-cadherin protein posttranscriptionally. Results of this study provide a molecular basis by which PROX1 promotes tumorigenesis of colon cancer. For details, see the article by Lu and colleagues on page 6416 of this issue.